Breaking News Instant updates and real-time market news.

IMMU

Immunomedics

$3.15

0.15 (5.00%)

16:20
11/18/16
11/18
16:20
11/18/16
16:20

Immunomedics confirms venBio's submitted notice of board director nominations

Immunomedics confirmed that venBio Select Advisor LLC has submitted a notice of nomination of four director candidates to stand for election to the Immunomedics board of directors at the company's 2016 Annual Meeting of Stockholders to be held on December 14, 2016. The company issued the following statement: "The Immunomedics Board of Directors and management team are committed to acting in the best interests of the company and all stockholders and regularly seeks qualified candidates for the Board. To that end, while venBio did not engage in discussions with the company prior to nominating a majority slate for election to the Board just four weeks prior to the upcoming 2016 Annual Meeting, Immunomedics' Governance and Nominating Committee will consider venBio's director candidates and respond in due course. Immunomedics has achieved a number of important milestones in 2016, including delivering positive Phase 2 clinical trial results of IMMU-132 in patients with metastatic triple-negative breast cancer, which have been submitted for publication; achieving our timetable for the manufacturing of clinical materials for the Phase 3 confirmatory trial in TNBC; and nearing completion of enrolling 100 patients into our ongoing open-label Phase 2 trial by year-end 2016. The company has also retained Greenhill & Co. to pursue licensing and other strategic activities with regard to preclinical and clinical pipeline products as well as platform technologies. The company is at a pivotal point in its growth trajectory as it prepares to submit an accelerated approval application to the FDA for IMMU-132 in mid-2017 and believes disruption in its strategy at this time could destroy value and potentially disrupt the company's clinical trial activities for late-stage cancer patients. Additionally, as previously announced, at the annual meeting of the American Society of Hematology in December 2016, the company will premiere a new antibody-drug conjugate known as IMMU-140 and the company anticipates delivering interim results for IMMU-132 at a symposium on genitourinary cancers to be held in early 2017. Immunomedics is well-positioned to execute on the company's strategy, drive innovation in the targeted treatment of cancer, autoimmune disorders and other serious diseases and enhance stockholder value, and perhaps most importantly help patients suffering from cancer."

IMMU Immunomedics
$3.15

0.15 (5.00%)

05/06/16
JEFF
05/06/16
UPGRADE
Target $5
JEFF
Buy
Immunomedics upgraded to Buy from Hold at Jefferies
Jefferies analyst Chris Howerton upgraded Immunomedics to Buy saying IMMU-132 continues to demonstrate impressive clinical data in solid tumors. The analyst sees a greater likelihood of Immunomedics securing a partner for the asset following recent data. He raised his price target for the shares to $5.00 from $1.50.
06/21/16
WELS
06/21/16
DOWNGRADE
WELS
Market Perform
Immunomedics downgraded to Market Perform from Outperform at Wells Fargo
10/06/16
JEFF
10/06/16
INITIATION
Target $5.5
JEFF
Buy
Immunomedics assumed with a Buy at Jefferies
Jefferies analyst Matthew Andrews assumed coverage of Immunomedics with a Buy rating and raised his price target for the shares to $5.50 from $5. IMMU-132's "promising results" in Triple Negative breast cancer sets the stage for a partnership deal in the coming months, Andrews tells investors in a research note.
10/18/16
JEFF
10/18/16
NO CHANGE
JEFF
Jefferies sees 'attractive buying opportunities' in Biotech
The Jefferies Biotechnology team sees "attractive buying opportunities" amidst the pre-election weakness. While volatility will likely continue into the election, valuation multiples are near-historic lows and policy concerns, while valid, are likely overstated, the analysts tell investors in a research note. They recommend using the weakness to buy select names ahead of a potential improvement in sentiment. Jefferies likes Gilead (GILD) and Celgene (CELG) among large-caps, The Medicines Co. (MDCO), Alkermes (ALKS) and Vertex (VRTX) among mid-caps, and Alder Biopharmaceuticals (ALDR), Cempra (CEMP), Ultragenyx (RARE) and Immunomedics (IMMU) among small-caps.

TODAY'S FREE FLY STORIES

08:32
01/18/18
01/18
08:32
01/18/18
08:32
General news
Jobless Claims data reported »

Week of 1/13 Jobless…

ESIO

Electro Scientific

$22.01

1.91 (9.50%)

08:32
01/18/18
01/18
08:32
01/18/18
08:32
Recommendations
Electro Scientific analyst commentary  »

Electro Scientific target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

08:32
01/18/18
01/18
08:32
01/18/18
08:32
General news
Philadelphia Fed Business Outlook Survey General Conditions Index data reported »

January Philadelphia Fed…

08:32
01/18/18
01/18
08:32
01/18/18
08:32
Conference/Events
Morgan Stanley healthcare analysts hold an analyst/industry conference call »

Healthcare Analyst…

CAA

CalAtlantic

$63.26

1.77 (2.88%)

08:32
01/18/18
01/18
08:32
01/18/18
08:32
Hot Stocks
CalAtlantic acquires Utah-based Candlelight Homes »

CalAtlantic Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIOT

Riot Blockchain

$17.76

-0.52 (-2.84%)

08:32
01/18/18
01/18
08:32
01/18/18
08:32
Hot Stocks
Riot Blockchain submits bidder registration for U.S. Marshals auction of bitcoin »

Riot Blockchain (RIOT)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

HEI

Heico

$96.89

0.47 (0.49%)

, HEI.A

HEICO

$79.40

-0.05 (-0.06%)

08:31
01/18/18
01/18
08:31
01/18/18
08:31
Hot Stocks
Heico share prices adjusted for stock split »

HEICO Corporation…

HEI

Heico

$96.89

0.47 (0.49%)

HEI.A

HEICO

$79.40

-0.05 (-0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UQM

UQM Technologies

$1.42

0.01 (0.71%)

08:31
01/18/18
01/18
08:31
01/18/18
08:31
Hot Stocks
UQM Technologies receives $1.2M explosion-proof E-drive system order from KESHI »

UQM Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBM

Hudbay Minerals

$10.05

0.1 (1.01%)

08:30
01/18/18
01/18
08:30
01/18/18
08:30
Downgrade
Hudbay Minerals rating change  »

Hudbay Minerals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVX

Chevron

08:30
01/18/18
01/18
08:30
01/18/18
08:30
Downgrade
Chevron rating change  »

Chevron downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

SLB

Schlumberger

$77.21

0.04 (0.05%)

08:30
01/18/18
01/18
08:30
01/18/18
08:30
Recommendations
Schlumberger analyst commentary  »

Schlumberger positioned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

IXYS

IXYS

08:30
01/18/18
01/18
08:30
01/18/18
08:30
Options
Two option delistings on January 18th »

Option delistings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:30
01/18/18
01/18
08:30
01/18/18
08:30
General news
U.S. Philladephia Fed index preview: »

U.S. Philladephia Fed…

HCC

Warrior Met Coal

$27.86

0.47 (1.72%)

08:26
01/18/18
01/18
08:26
01/18/18
08:26
Hot Stocks
Warrior Met Coal upgraded to B by S&P Global Ratings »

Warrior Met Coal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

ARGS

Argos Therapeutics

$0.16

0.0214 (15.30%)

08:26
01/18/18
01/18
08:26
01/18/18
08:26
Hot Stocks
Argos Therapeutics announces one-for-twenty reverse stock split »

Argos Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSLR

Vivint Solar

08:25
01/18/18
01/18
08:25
01/18/18
08:25
Downgrade
Vivint Solar rating change  »

Vivint Solar downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRAM

Everspin Technologies

$8.21

-0.19 (-2.26%)

, SGH

Smart Global

$36.68

0.93 (2.60%)

08:25
01/18/18
01/18
08:25
01/18/18
08:25
Hot Stocks
Everspin Technologies and Smart Global partner in nvNITRO acclerator »

Everspin Technologies…

MRAM

Everspin Technologies

$8.21

-0.19 (-2.26%)

SGH

Smart Global

$36.68

0.93 (2.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

ESIO

Electro Scientific

$22.01

1.91 (9.50%)

08:25
01/18/18
01/18
08:25
01/18/18
08:25
Recommendations
Electro Scientific analyst commentary  »

Electro Scientific price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

AAPL

Apple

$179.10

2.91 (1.65%)

08:25
01/18/18
01/18
08:25
01/18/18
08:25
Periodicals
Apple iPhones, Mac computers affected by "text bomb" security flaw, CNBC says »

A software developer has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

ISRG

Intuitive Surgical

$431.10

11.03 (2.63%)

08:25
01/18/18
01/18
08:25
01/18/18
08:25
Recommendations
Intuitive Surgical analyst commentary  »

Intuitive Surgical price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

08:25
01/18/18
01/18
08:25
01/18/18
08:25
General news
Fedspeak from Cleveland Fed hawk Mester »

Fedspeak from Cleveland…

FSLR

First Solar

$72.00

0.78 (1.10%)

08:24
01/18/18
01/18
08:24
01/18/18
08:24
Downgrade
First Solar rating change  »

First Solar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSGP

CoStar Group

$321.96

2.9 (0.91%)

08:22
01/18/18
01/18
08:22
01/18/18
08:22
Recommendations
CoStar Group analyst commentary  »

CoStar Group price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

ARWR

Arrowhead

$5.72

0.12 (2.14%)

08:22
01/18/18
01/18
08:22
01/18/18
08:22
Syndicate
Arrowhead 10M share Spot Secondary priced at $5.25 »

The deal was up-sized to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

MANT

ManTech

$52.14

0.8 (1.56%)

08:22
01/18/18
01/18
08:22
01/18/18
08:22
Hot Stocks
ManTech awarded $35.9M Navy contract for combat ID systems »

ManTech announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.